User profiles for Krishna Aluri

Krishna C. Aluri

Senior Scientist at Novo Nordisk
Verified email at husky.neu.edu
Cited by 782

[HTML][HTML] Best practices and benchmarks for intact protein analysis for top-down mass spectrometry

…, L Fornelli, LF Schachner, Z Lin, JL Lippens, KC Aluri… - Nature …, 2019 - nature.com
One gene can give rise to many functionally distinct proteoforms, each of which has a
characteristic molecular mass. Top-down mass spectrometry enables the analysis of intact proteins …

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates

…, H Attarwala, A Sehgal, Q Wang, K Aluri… - Nucleic acids …, 2017 - academic.oup.com
Covalent attachment of a synthetic triantennary N-acetylagalactosamine (GalNAc) ligand to
chemically modified siRNA has enabled asialoglycoprotein (ASGPR)-mediated targeted …

Discovery of a novel deaminated metabolite of a single-stranded oligonucleotide in vivo by mass spectrometry

J Li, J Liu, J Enders, M Arciprete, C Tran, K Aluri… - Bioanalysis, 2019 - Future Science
Aim: A novel single-stranded deaminated oligonucleotide metabolite resulting from a
REVERSIR™ oligonucleotide was discovered and identified in monkey liver after subcutaneous …

Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates

…, L Blair, X Zhang, B Das, C Tran, K Aluri… - Nucleic acids …, 2019 - academic.oup.com
For oligonucleotide therapeutics, chemical modifications of the sugar-phosphate backbone
are frequently used to confer drug-like properties. Because 2′-deoxy-2′-fluoro (2′-F) …

Oligonucleotide quantification and metabolite profiling by high-resolution and accurate mass spectrometry

J Liu, J Li, C Tran, K Aluri, X Zhang, V Clausen… - Bioanalysis, 2019 - Future Science
Aim: Advancements in RNA interference therapeutics have triggered development of
improved bioanalytical methods for oligonucleotide metabolite profiling and high-throughput …

[HTML][HTML] Loss of angiogenin function is related to earlier ALS onset and a paradoxical increase in ALS duration

KC Aluri, JP Salisbury, JHM Prehn, JN Agar - Scientific Reports, 2020 - nature.com
0.5–1% of ALS (Amyotrophic Lateral Sclerosis) and Parkinson's disease (PD) are associated
with mutations in the angiogenin (ANG). These mutations are thought to cause disease …

The nonclinical disposition and pharmacokinetic/pharmacodynamic properties of N-Acetylgalactosamine–conjugated small interfering RNA are highly predictable and …

…, D Ramsden, S Agarwal, S Agarwal, K Aluri… - Drug Metabolism and …, 2022 - ASPET
Conjugation of oligonucleotide therapeutics, including small interfering RNAs (siRNAs) or
antisense oligonucleotides, to N-acetylgalactosamine (GalNAc) ligands has become the …

The nonclinical disposition and PK/PD properties of GalNAc-conjugated siRNA are highly predictable and build confidence in translation to man

S Chong, S Agarwal, S Agarwal, KC Aluri… - Drug Metabolism and …, 2021 - ASPET
Conjugation of oligonucleotide therapeutics, including small interfering ribonucleic acids (siRNAs)
or antisense oligonucleotides (ASOs) to N-acetylgalactosamine (GalNAc) ligands has …

In vitro drug-drug interaction evaluation of GalNAc conjugated siRNAs against CYP450 enzymes and transporters

…, B Zerler, S Iqbal, J Jiang, V Clausen, K Aluri… - Drug Metabolism and …, 2019 - ASPET
Small interfering RNAs (siRNAs) represent a new class of medicines that are smaller (∼16,000
Da) than biologic therapeutics (>150,000 Da) but much larger than small molecules (<…

Pharmacokinetic evaluation of poorly soluble compounds formulated as nano-or microcrystals after intraperitoneal injection to mice

KC Aluri, K Sigfridsson, A Xue, N Hariparsad… - International Journal of …, 2023 - Elsevier
Intraperitonial (ip) delivery during initial stages of drug discovery can allow efficacy readouts
for compounds which have suboptimal pharmacokinetics (PK) due to poor physiochemical …